🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Nathan Bahary

Allegheny Health Network

ORCID: 0000-0001-7317-9118
MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 10 papers. Top paper: “Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine”.

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

New England Journal of Medicine(2013)10.1056/nejmoa1304369
N/A
1.3DataRank · unranked
6585 citations

Thomas Ervin, Francis P. Arena, E. Gabriela Chiorean, Jeffrey Infante, Fruzsina Molnar-Gabor +26 more

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

Annals of Oncology(2024)10.1016/j.annonc.2024.02.005
N/A
0.868DataRank · unranked
326 citations

S.L. Chan, R.K. Kelley, G. Lau, M. Kudo, W. Sukeepaisarnjaroen +198 more

A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-4042
N/A
0.817DataRank · unranked
231 citations

Nathan Bahary, Brian A. Boone, Aatur D. Singhi, Jennifer L. Miller-Ocuin, Daniel P. Normolle +14 more

Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size

Gut(2021)10.1136/gutjnl-2020-322595
N/A
0.759DataRank · unranked
157 citations

Lodewijk A.A. Brosens, Joo Young Kim, Roderick J. O’Sullivan, You-Na Sung, Ta‐Chiang Liu +51 more

Elucidating the Heterogeneity of Immunotherapy Response and Immune-Related Toxicities by Longitudinal ctDNA and Immune Cell Compartment Tracking in Lung Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1469
N/A
0.538DataRank · unranked
35 citations

Lavanya Sivapalan, Karlijn Hummelink, Archana Balan, James R. White, Noushin Niknafs +28 more

Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0535
N/A
0.512DataRank · unranked
12 citations

Devora Delman, Jiayi Yu, Mingen Liu, Joey H. Li, Liti Zhang +8 more

A phase II/III study of perioperative nivolumab and ipilimumab in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of a safety run-in—A trial of the ECOG-ACRIN Cancer Research Group (EA2174).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.4064
N/A
0.396DataRank · unranked
13 citations

Michelle Weitz, Paul J. Catalano, Michael K. Gibson, Lakshmi Rajdev, Onkar V. Khullar +15 more

A phase II/III study of perioperative nivolumab and ipilimumab in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: A trial of the ECOG-ACRIN Cancer Research Group (EA2174).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps4651
N/A
0.373DataRank · unranked
11 citations

Michelle Weitz, Michael K. Gibson, Lakshmi Rajdev, Onkar V. Khullar, Steven H. Lin +13 more

Intratumoral T cell clonality and survival in a randomized phase II study of preoperative autophagy inhibition in combination with gemcitabine and nab-paclitaxel treatment in patients with resectable pancreatic cancer.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.e16001
N/A
0.208DataRank · unranked
3 citations

Daniel Weber, Sagar N. Sharma, Aatur D. Singhi, Nathan Bahary, Wenjing Pan +7 more

Association of SMAD4 loss with response to neoadjuvant chemotherapy with the autophagy inhibitor hydroxychloroquine in patients with pancreatic adenocarcinoma.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.4_suppl.761
N/A
0DataRank · unranked
2 citations

Sijin Wen, Pavan Rao, Rajesh Ramanathan, Melissa E. Hogg, Amer H. Zureikat +6 more